Barrett's esophagus is an increasingly prevalent, preneoplastic disorder that results primarily from gastroduodenal reflux of acid and bile. The applicant group, which includes established investigators from Columbia University, the University of Pennsylvania, and the Mayo Clinic, propose a multidisciplinary, multicenter, translational research program to study the origins and pathogenesis of the disorder. The team, many of whom have collaborated in the past, will focus on the role of chronic inflammation and bile acids in the upregulation of established and novel stem cell markers, and possible ways to target these progenitor cells. The proposal builds on extensive basic science findings, the development of novel transgenic (L2-IL-1beta) and surgical models of BE/esophageal adenocarcinoma, and preliminary analyses of human BE tissues. The groups will bring to the network a very large BE patient population, experienced Barrett's clinical investigators, and bench researchers with extensive experience with stem cells and inflammatory models of Gl cancer. Three projects are proposed. Project 1 will focus on the role of Notch signaling in models of Barrett's esophagus, and will determine the effects of Notch inhibition or Notch activation on progression to dysplasia. Project 2 will seek to characterize the cell of origin in Barrett's esophagus in our mouse models. We will use constituitive and inducible mouse models of Cre expression to lineage trace active and quiescent progenitors that are upregulated in our model and in human BE. Additionally, we will carry out a pilot clinical trial using an antagonist of a G-protein coupled receptor expressed on progenitor cells upregulated in BE. Finally, Project 3 will aim to identify novel biomarkers and gene signatures in BE, correlating data sets from animal and human models, clarifying the importance of non-goblet cell columnar epithelium and changes in the gastric cardia. We will also assemble a cohort of patients undergoing radiofrequency ablation, identifying biomarkers of response to therapy and using successfully ablated patients as a novel human model to study the development of BE. Overall, these studies aim to elucidate the earliest stages and cell types that contribute to BE pathogenesis in order to better stratify risk and develop preventive therapies.

Public Health Relevance

The goal of the present proposal is to generate a dear understanding of the mechanisms underlying the development of Barrett's esophagus and EAC, and subsequently to transform this knowledge into clinical practice that will improve patient outcomes and decrease the disease burden of EAC. Our novel preclinical models serve as the foundation for testing these hypotheses, which are then brought ultimately to the clinical arena in a true translational. bench-to bedside approach through biomarker and chemoprevention studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
3U54CA163004-04S1
Application #
8844119
Study Section
Special Emphasis Panel (ZCA1 (O1))
Program Officer
Ogunbiyi, Peter
Project Start
2011-09-26
Project End
2016-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
4
Fiscal Year
2014
Total Cost
$174,160
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Fecteau, Ryan E; Kong, Jianping; Kresak, Adam et al. (2016) Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia. JAMA Oncol 2:1333-1339
Critchley-Thorne, Rebecca J; Duits, Lucas C; Prichard, Jeffrey W et al. (2016) A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus. Cancer Epidemiol Biomarkers Prev 25:958-68
Bansal, Ajay; Gupta, Vijayalaxmi; Wang, Kenneth (2016) MicroRNA Expression Signatures During Malignant Progression From Barrett's Esophagus. J Cell Biochem 117:1288-95
Chan, Daniel K; Leggett, Cadman L; Wang, Kenneth K (2016) Diagnosing gastrointestinal illnesses using fecal headspace volatile organic compounds. World J Gastroenterol 22:1639-49
Schellnegger, Raphael; Quante, Anne; Rospleszcz, Susanne et al. (2016) Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal Adenocarcinoma. Cancer Prev Res (Phila) :
Kong, Jianping; Whelan, Kelly A; Laczkó, Dorottya et al. (2016) Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress. Mol Carcinog 55:1526-1541
Snider, Erik J; Freedberg, Daniel E; Abrams, Julian A (2016) Potential Role of the Microbiome in Barrett's Esophagus and Esophageal Adenocarcinoma. Dig Dis Sci 61:2217-25
Pattison, Amanda M; Blomain, Erik S; Merlino, Dante J et al. (2016) Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins. Infect Immun 84:3083-91
Small, Aaron J; Sutherland, Scott E; Hightower, Jessica S et al. (2015) Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high-grade dysplasia versus intramucosal carcinoma in Barrett's esophagus. Gastrointest Endosc 81:1158-66.e1-4
Stachler, Matthew D; Taylor-Weiner, Amaro; Peng, Shouyong et al. (2015) Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet 47:1047-55

Showing the most recent 10 out of 43 publications